NBIO (Nascent Biotech) Accounts Payable: $0.68 Mil (As of Jun. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Nascent Biotech Accounts Payable?

Nascent Biotech NBIO Accounts Payable is $0.68 Mil as of Jun. 2024.

Nascent Biotech's Accounts Payable for the quarter that ended in Jun. 2024 was $0.68 Mil.

Nascent Biotech's quarterly Accounts Payable increased from Dec. 2023 ($0.48 Mil) to Mar. 2024 ($0.69 Mil) but then declined from Mar. 2024 ($0.69 Mil) to Jun. 2024 ($0.68 Mil).

Nascent Biotech's annual Accounts Payable declined from Mar. 2022 ($0.78 Mil) to Mar. 2023 ($0.50 Mil) but then increased from Mar. 2023 ($0.50 Mil) to Mar. 2024 ($0.69 Mil).

Nascent Biotech Accounts Payable Related Terms

Nascent Biotech Accounts Payable Historical Data

* Premium members only.

The historical data trend for Nascent Biotech's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nascent Biotech Accounts Payable Chart

Nascent Biotech Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Accounts Payable
Get a 7-Day Free Trial 0.85 0.64 0.78 0.50 0.69

Nascent Biotech Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.51 0.48 0.69 0.68

Nascent Biotech Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of $0.68 Mil mean?
Nascent Biotech (NBIO) has a Accounts Payable of $0.68 Mil as of Jun. 2024. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Nascent Biotech and its competitors.
Is Nascent Biotech's Accounts Payable too high?
Nascent Biotech's current Accounts Payable is $0.68 Mil.
How does Nascent Biotech's Accounts Payable compare to BTAX and PXMD?
Nascent Biotech's Accounts Payable of $0.68 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Biotechnology company?
A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Nascent Biotech and its competitors. Nascent Biotech's current Accounts Payable is $0.68 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nascent Biotech stock overvalued right now?
Nascent Biotech (NBIO) has a current Accounts Payable of $0.68 Mil. The current Accounts Payable is $0.68 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Nascent Biotech (NBIO), the current Accounts Payable is $0.68 Mil as of Jun. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Nascent Biotech Business Description

Address 631 US Hwy 1, Suite 407, N Palm Beach, FL, USA, 33408
Nascent Biotech Inc is a United States-based clinical-stage biopharmaceutical company. The company is focused on the development and delivery of human antibodies and cytokine responses to the treatment of cancer. The company's products include Pritumumab, CLNH5, and MultiPharm. The company is engaged in the development of Pritumumab which would be used for the treatment of brain cancer and pancreatic cancer. The company is also exploring the use of Pritumumab against other viruses.